Mylan NV (MYL)

38.19
0.80 2.05
NASDAQ : Health Technology
Prev Close 38.99
Open 38.70
Day Low/High 37.78 / 39.12
52 Wk Low/High 30.69 / 47.82
Volume 2.54M
Avg Volume 3.85M
Exchange NASDAQ
Shares Outstanding 515.57M
Market Cap 19.97B
EPS 1.30
P/E Ratio 45.03
Div & Yield N.A. (N.A)

Latest News

Mylan Launches Authorized Generic Of Ampyra® Tablets

Mylan Launches Authorized Generic Of Ampyra® Tablets

- Mylan's Dalfampridine Extended-Release Tablets, 10 mg, are indicated for patients with multiple sclerosis -

Mylan And Fujifilm Kyowa Kirin Biologics Receive European Marketing Authorization For Hulio®, Biosimilar Adalimumab

Mylan And Fujifilm Kyowa Kirin Biologics Receive European Marketing Authorization For Hulio®, Biosimilar Adalimumab

HERTFORDSHIRE, England and PITTSBURGH and TOKYO, Sept. 20, 2018 /PRNewswire/ --  Mylan N.

Theravance Biopharma And Mylan Report New Data From Phase 3 Studies Of YUPELRI™ (revefenacin) In Oral Presentation At The European Respiratory Society International Congress

Theravance Biopharma And Mylan Report New Data From Phase 3 Studies Of YUPELRI™ (revefenacin) In Oral Presentation At The European Respiratory Society International Congress

Reduction in Rates of COPD Exacerbations Observed in COPD Patients Treated with YUPELRITM Compared to Placebo and Tiotropium (Spiriva® HandiHaler®)

Mylan Adds To Cardiovascular Portfolio With Launch Of First Generic Of Brevibloc® Injection In Single-Dose Bags

Mylan Adds To Cardiovascular Portfolio With Launch Of First Generic Of Brevibloc® Injection In Single-Dose Bags

- Esmolol Hydrochloride in Sodium Chloride Injection is used to control heart rate -

Theravance Biopharma And Mylan To Report New Data From Phase 3 Studies Of YUPELRI™ (revefenacin) In Oral Presentation At European Respiratory Society International Congress 2018

Theravance Biopharma And Mylan To Report New Data From Phase 3 Studies Of YUPELRI™ (revefenacin) In Oral Presentation At European Respiratory Society International Congress 2018

Presentation to Highlight COPD Exacerbation Rates Observed in Phase 3 Program of YUPELRI in Patients with Moderate to Very Severe COPD

Teva Notches Win With FDA Approval of Generic EpiPen

Teva Notches Win With FDA Approval of Generic EpiPen

The regulatory agency has authorized the sale of the drugmaker's generic version of Mylan's EpiPen.

Mylan Launches First Generic For Adcirca® Tablets

Mylan Launches First Generic For Adcirca® Tablets

- Tadalafil is indicated in the treatment of pulmonary arterial hypertension to improve exercise ability -

This Market Isn't Weak, It's Just Tired

The market needs a pullback.

Stocks End Flat Amid Rising U.S.-China Trade Tensions; Disney, Tesla Slip

Stocks End Flat Amid Rising U.S.-China Trade Tensions; Disney, Tesla Slip

Stocks ended mixed on Wednesday as a push from strong corporate earnings is muted by continued trade tensions between the U.S. and China.

EpiPen Maker Mylan to Explore Options, Shares Sink

EpiPen Maker Mylan to Explore Options, Shares Sink

The drugmaker 's board said the U.S. public markets 'continue to underappreciate and undervalue' the company's diversified business.

Statement From Mylan's Board Of Directors

Statement From Mylan's Board Of Directors

HERTFORDSHIRE, England, Aug. 8, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Mylan Reports Second Quarter 2018 Results And Updates 2018 Guidance

Mylan Reports Second Quarter 2018 Results And Updates 2018 Guidance

HERTFORDSHIRE, England and PITTSBURGH, Aug. 8, 2018 /PRNewswire/ --  Mylan N.

Tesla Is Not Worth $420, No Matter What Musk Says: Market Recon

Tesla Is Not Worth $420, No Matter What Musk Says: Market Recon

The erratic CEO and awful fundamentals make it impossible to value TSLA -- despite attractive technicals.

Mylan To Release Second Quarter 2018 Financial Results On August 8, 2018

Mylan To Release Second Quarter 2018 Financial Results On August 8, 2018

HERTFORDSHIRE, England, and PITTSBURGH, July 31, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.

Mylan And Fujifilm Kyowa Kirin Biologics Announce Positive CHMP Opinion For Hulio™, Biosimilar Adalimumab

Mylan And Fujifilm Kyowa Kirin Biologics Announce Positive CHMP Opinion For Hulio™, Biosimilar Adalimumab

HERTFORDSHIRE, England and PITTSBURGH, and TOKYO, July 27, 2018 /PRNewswire/ --  Mylan N.

Mylan Becomes #36 Most Shorted Nasdaq 100 Component, Replacing Cognizant Technology Solutions

Mylan Becomes #36 Most Shorted Nasdaq 100 Component, Replacing Cognizant Technology Solutions

The most recent short interest data has been released for the 07/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Mylan Again Defeats Allergan's Efforts To Deny Patients Access To More Affordable Medicine

Mylan Again Defeats Allergan's Efforts To Deny Patients Access To More Affordable Medicine

U.S. Court of Appeals for the Federal Circuit rejects Allergan's attempt to use tribal sovereign immunity to avoid Restasis® patent challenge

5 Big Biotech Stories to Watch

5 Big Biotech Stories to Watch

The biotech and pharmaceutical industries have had some big news in recent weeks. Here's what you should know to stay up-to-date.

Mylan Adds To Central Nervous System Portfolio With Launch Of Generic Exelon® Patch

Mylan Adds To Central Nervous System Portfolio With Launch Of Generic Exelon® Patch

- The launch of Rivastigmine Transdermal System highlights Mylan's continued investment in difficult-to-manufacture products -

10 Large-Cap Stocks With At Least 40% Upside Potential

10 Large-Cap Stocks With At Least 40% Upside Potential

On the search for promising stocks, give these 10 names from Goldman Sachs a consideration.

Adamis Pharma Shares Soar on Deal With Novartis for Epipen Competitor

Adamis Pharma Shares Soar on Deal With Novartis for Epipen Competitor

Adamis' device to treat allergic reactions should compete effectively with Mylan's popular EpiPen, according to an analyst.

Lupin And Mylan Partner To Commercialize Enbrel® (Etanercept) Biosimilar

Lupin And Mylan Partner To Commercialize Enbrel® (Etanercept) Biosimilar

MUMBAI, India and HERTFORDSHIRE, England and PITTSBURGH, June 28, 2018 /PRNewswire/ -- Pharma major Lupin Limited (Lupin) and global pharmaceutical company Mylan N.

China Pledges Help With Fentanyl Imports; Says U.S. Must Curb Opioid Demand

China Pledges Help With Fentanyl Imports; Says U.S. Must Curb Opioid Demand

Despite a growing trade war between the U.S, and China, drug officials in that country have pledged to try to stop the flow of fentanyl into the U.S.

Mylan Launches Generic Angiomax® Injection

Mylan Launches Generic Angiomax® Injection

- Bivalirudin for Injection is an anticoagulant intended for use with aspirin -

Mylan Slumps in After-Hours Trading on Generic Advair Update

Mylan Slumps in After-Hours Trading on Generic Advair Update

The drugmaker says the FDA will issue a complete response letter on June 27.

Alibaba, Applied Materials, Chesapeake Energy: 'Mad Money' Lightning Round

Alibaba, Applied Materials, Chesapeake Energy: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Applied Materials, Chesapeake Energy, Endo Pharmaceuticals, Mylan Laboratories, JD.com, Alibaba and more.

Markets Shrug Off N. Korea: Cramer's 'Mad Money' Recap (Tuesday, June 12 2018)

Markets Shrug Off N. Korea: Cramer's 'Mad Money' Recap (Tuesday, June 12 2018)

Jim Cramer explains what U.S. markets are focusing on now that North Korean nuclear worries have faded.

Mylan Becomes #32 Most Shorted Nasdaq 100 Component, Replacing Netflix

Mylan Becomes #32 Most Shorted Nasdaq 100 Component, Replacing Netflix

The most recent short interest data has been released for the 05/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

TheStreet Quant Rating: C (Hold)